Telesis Bio

Telesis Bio's business model centers on the manufacturing and sale of laboratory instruments, reagents, and related services to a global client base that includes pharmaceutical companies, academic institutions, and contract research organizations. The company generates revenue through the sale of its products and services, reporting a trailing twelve-month revenue of $16.3 million as of June 2024. Its offerings are designed to accelerate research and development in areas like biologics drug discovery, vaccine development, personalized medicine, and cell and gene therapy.

The company's flagship product line is the BioXp® system, an automated benchtop workstation that enables researchers to convert a digital DNA sequence into synthetic genes, clones, variant libraries, and mRNA overnight. This platform consolidates and automates the entire synthesis, cloning, and amplification workflow, significantly reducing turnaround times compared to traditional methods. More recently, Telesis Bio launched the Gibson SOLA™ platform, a next-generation enzymatic DNA synthesis (EDS) technology. SOLA uses a novel enzymatic approach to build DNA in blocks, which results in higher fidelity and faster workflows. This platform integrates with standard lab automation, allowing scientists to maintain control over their intellectual property and timelines by bringing nucleic acid synthesis in-house. The company has secured collaborations and licensing agreements with major industry players like Regeneron and Beckman Coulter Life Sciences to drive the adoption of its technologies.